Stella Pharma Corp Signs Basic Agreement With QST Hospital for New Particle Beam Therapy

TOKYO, Jul 28 (Pulse News Wire) – Stella Pharma Corporation (4888.T) signed a basic agreement with National Institutes for Quantum Science and Technology (QST) Hospital to explore a novel particle beam therapy combining its boron drug Steboronine with QST's particle research equipment. The project differs from traditional Boron Neutron Capture Therapy (BNCT) by utilizing particle beams instead of neutron beams to activate the drug within the body, potentially adding a new mechanism to existing treatments.

Under the agreement, the companies aim to conduct foundational studies, non-clinical trials, clinical trials, and regulatory approval discussions. The collaboration leverages QST’s advanced research infrastructure and expertise in particle beams alongside Stella Pharma’s accumulated knowledge in boron drugs.

The initiative seeks to validate the feasibility of a new cancer treatment method that combines Steboronine with particle beams distinct from neutrons. Looking ahead, the impact on Stella Pharma’s fiscal 2027 performance is expected to be minor.

Further details on the study contents and progress will be disclosed promptly as negotiations advance.